Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($6.81) EPS for the quarter, missing the consensus estimate of ($6.25) by ($0.56), Zacks reports.
Theriva Biologics Stock Performance
TOVX opened at $1.35 on Friday. Theriva Biologics has a 12 month low of $1.24 and a 12 month high of $17.11.
Wall Street Analysts Forecast Growth
Separately, Maxim Group cut their price target on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday.
Theriva Biologics Company Profile
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Theriva Biologics
- What is the S&P/TSX Index?
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Canadian Penny Stocks: Can They Make You Rich?
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
